Get the Stockscreener App
7.76
3.00%
-0.24
After Hours:
8.00
0.24
+3.09%
Immunitybio Inc stock is traded at $7.76, with a volume of 17.47M.
It is down -3.00% in the last 24 hours and up +0.78% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.00
Open:
$7.96
24h Volume:
17.47M
Relative Volume:
0.72
Market Cap:
$8.13B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-19.91
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-4.43%
1M Performance:
+0.78%
6M Performance:
+262.62%
1Y Performance:
+177.14%
1-Day Range:
$7.33
$7.96
1-Week Range:
$7.33
$8.53
52-Week Range:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.76 | 8.38B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive N - PharmiWeb.com
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
IBRX Stock Jumps Overnight After Major FDA Review Win For Anktiva In Bladder Cancer - Stocktwits
FDA accepts ImmunityBio’s application for Anktiva expansion By Investing.com - Investing.com Nigeria
FDA accepts ImmunityBio’s application for Anktiva expansion - Investing.com
FDA sets Jan. 6, 2027 for drug that helped patients avoid bladder removal - Stock Titan
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 - Yahoo Finance
IBRX Stock’s Decline Makes Retail See ‘Incredible’ Buying Opportunity After Anktiva + BCG Therapy Delivered Favorable Results - Stocktwits
IBRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - marketscreener.com
ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies - Benzinga
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer - Yahoo Finance
ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM (IBRX) - Seeking Alpha
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes - PR Newswire Canada
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 - Business Wire
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership - Yahoo Finance
ImmunityBio Secures Exclusive U.S. Agreement to Supply Tokyo Strain BCG, Aiming to Resolve Bladder Cancer Treatment Shortage - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Key facts: ImmunityBio Wins Five US Patents for Anktiva; US Supply Deal - TradingView
ImmunityBio Secures Exclusive Tokyo-172 BCG Rights in U.S. - TipRanks
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th - GlobeNewswire Inc.
ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory - TradingView
Exclusive Tokyo BCG supply deal expands ImmunityBio (NASDAQ: IBRX) options - Stock Titan
ImmunityBio Secures Exclusive US Rights To Tokyo Strain BCG To Address Chronic Bladder Cancer Treatment Shortage - BioPharma APAC
ImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess - GuruFocus
$IBRX DEADLINE: Immunitybio Inc. Investors Who Lost Money Should Contact Block & Leviton Before May 26th Deadline - marketscreener.com
ImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm - PR Newswire
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
IMMUNITYBIO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors ... - Caledonian Record
IMMUNITYBIO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, - GlobeNewswire
Kessler Topaz Meltzer & Check, LLP Announces the Filing of - GlobeNewswire
IBRX 8-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman - PR Newswire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the ... - Caledonian Record
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ImmunityBio Shares Rise After Securing Five New U.S. Patents for Bladder Cancer Therapy (IBRX) - Yahoo Finance
What's Going On With ImmunityBio Stock Monday?ImmunityBio (NASDAQ:IBRX) - Benzinga
Why Is IBRX Stock Rising Today? - Stocktwits
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open - TechStock²
ImmunityBio stock gains on five new U.S. patent awards - Investing.com India
ImmunityBio announces comprehensive U.S. patents covering combination of Anktiva with BCG for cancer treatment - marketscreener.com
ImmunityBio receives five U.S. patents for cancer treatment - Investing.com
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 - Business Wire
ImmunityBio Secures Exclusive Rights to Develop, Commercialize Tokyo-172 BCG in US - marketscreener.com
ImmunityBio Signs exclusive US agreement with Japan BCG Laboratory - BioSpectrum Asia
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of ImmunityBio, Inc. to Contact the Firm Today! - ACCESS Newswire
Countdown begins for IBRX founder Patrick Soon-Shiong’s much anticipated AUA talk – a look at what he intends to address on Saturday - MSN
IBRX Stock Rises Overnight: Investors Eye FDA Workshop On Anktiva After Exclusive Japan BCG Deal - Stocktwits
ImmunityBio announces partnership to expand access to Anktiva across 30 countries - MSN
ImmunityBio (IBRX) Secures U.S. Development Rights for Tokyo BCG Strain - GuruFocus
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):